Krystal Biotech, Inc. (KRYS) News
Filter KRYS News Items
KRYS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KRYS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest KRYS News From Around the Web
Below are the latest news stories about KRYSTAL BIOTECH INC that investors may wish to consider to help them evaluate KRYS as an investment opportunity.
3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings GrowthAs the U.S. stock market inches higher in a holiday-shortened session, with indices like the Nasdaq Composite and S&P 500 posting modest gains, investors are keeping a close eye on growth stocks that demonstrate robust potential amid fluctuating economic conditions. In this context, companies with high insider ownership can be particularly appealing, as significant insider stakes often signal confidence in the company's future prospects and alignment of interests between management and... |
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?It is hard to get excited after looking at Krystal Biotech's (NASDAQ:KRYS) recent performance, when its stock has... |
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707. |
Krystal Biotech Says Initial Results From Kyanite-1 Trial Show 'Early Evidence' of Monotherapy ActivityKrystal Biotech (KRYS) said Wednesday that preliminary results from its Kyanite-1 clinical trial sho |
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung CancerPreliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, an |
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat rare respiratory diseases. |
Krystal Biotech announces initial update for KB408, KB407Krystal Biotech (KRYS) clinical data updates for both KB408 and KB407, the Company’s clinical-stage, inhaled genetic medicine programs in Phase 1 for the treatment of rare respiratory diseases. Today’s updates include molecular data from multiple patients demonstrating SERPINA1 delivery and alpha-1 antitrypsin, AAT, expression within the respiratory tract following KB408 administration as well as safety and tolerability data for both KB407 and KB408 that, taken together, highlight the potential |
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic LevelsClear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients and KB407 for patients with cystic fibrosis were safe and well tolerated at all dosing regimens evaluated to date Conditional sanctioning of the KB407 Phase 1 CF Study CORAL-1 protocol by CFF TDN Investor call and webcast to be held December 12 at 8:30 am ET to discuss data update PITTSBURGH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company |
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis BullosaCHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) cancelled the Oral Explanation regarding the Company’s Marketing Authorization Application for beremagene geperpavec-svdt (B-VEC |